Multipurpose Prevention Technologies (MPTs) are an innovative class of products that deliver varied combinations of HIV prevention, other STI prevention, and contraception and will improve the lives of women and families worldwide.
This database includes MPT products that are currently in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Click on the tables for MPT products in the development pipeline, listed by:
Bill & Melinda Gates Foundation
NIH: Interagency Agreements to USAID
Active Ingredient:
Levonorgestrel
Tenofovir (TFV)
Product Indications:
HIV
HSV-2
Pregnancy
Description: Polyurethane, dual-reservoir ring designed for 3 months of continuous use, or with up to 3 days intermittent removal. The first-in-women Phase I trial (CONRAD-128) completed in 2016 and successfully met all performance benchmarks. An expanded Phase I study (CONRAD-138) was completed in early 2019; results expected mid-2020. A first-in-kind study to evaluate MPT IVRs in Africa, the CDC Kisumu Combined Ring Study (CONRAD B17-144) was completed in late 2019; results expected in late 2020.
